Pfizer: Blockbuster success is a double-edged sword

I wrote this article for FT in 2005, but after reading news on Pfizer it feels like I could have written it today.

Pfizer Blockbuster success is a double-edged sword

I wrote this article for FT in 2005, but after reading news on Pfizer it feels like I could have written it today.

Here are some excerpts from the article:

  1. Blockbuster success is a double-edged sword. In this litigious society a discovery of side-effects brings an army of tort lawyers to the doorsteps of pharmaceutical companies.
  2. The demographic trends of ageing baby boomers will push demand for the pharmaceuticals into the stratosphere for a long time. However, investors should add another dimension to their analysis – product diversification.  Companies that have a high concentration of sales in just a few blockbuster drugs should either be avoided or have a much smaller place in the portfolio. Also, investors should temper valuation premium expectations for the overall sector as it is unlikely to return to its old levels.
  3. Medical device/instrument companies are likely to take over the leadership from pharmaceutical companies and inherit the premium valuation.  [Zimmer (ZMH), Biomet (BMET) come to mind here].  They will reap the rewards from the baby boomers’ desire for longer and healthier lives. With few exceptions, medical device/instruments companies have a much more diversified product line.
  4. Companies that provide services to the pharmaceutical industry are a good sidedoor to participate in the industry’s future prosperity without subjecting investors to the all risks. IMS Health (RX), a provider of market intelligence to the pharmaceutical industry, comes to mind as a good side position. It has all the qualities of a pharmaceutical company: strong competitive advantage, terrific return on capital, monopoly-like profit margins, great cash flows, very reasonable valuation and good consistent growth prospects ahead, without all the aforementioned risks. [I no longer own RX, but it maybe a good time revisit the stock.]

Please read the following important disclosure here.

New to investing?

Explore these valuable guides to get started.

Related Articles

Oil pumpjack and AI servers

Oil, Commodities, AI, and Cyclicality

Trillions of dollars are being spent on the supply side, while the demand side is uncertain. This is what would keep me up at night if I owned these stocks.
The Values of Value Investing

The Values of Value Investing

What are the real values of value investing? It’s not just cheap stocks—it’s quality, growth, and the wisdom to know the difference.
The World's Best-Prepared Patient

The World’s Best-Prepared Patient

Nobody in this equation is flawless: not doctors, not us, and not even AI. It hallucinates, making up stories like a Hollywood screenwriter. But it also has perfect recall and lacks the myopic vision of human beings. … That’s the model. Not AI instead of your doctor.
The AI Hangover Is Coming. The Pandemic Already Showed Us How It Ends

The AI Hangover Is Coming. The Pandemic Already Showed Us How It Ends.

We don’t have to go decades back to find an analogy. Just look back a few years, to the pandemic. We all lived through it, most of us in sweatpants. And it offers a near-perfect preview of what is about to happen in AI.

Leave a Comment